Literature DB >> 10410853

Update on inherited bullous dermatoses.

M P Marinkovich1.   

Abstract

Bullous diseases are becoming increasingly better understood owing to the active research which has taken place in this field over the past decade. Advances in understanding of bullous disease pathophysiology is translating into clinical applications for diagnosis and therapy that will greatly enhance the quality of care bullous disease patients may receive now and in the future. This review focuses on the progress which has been achieved in inherited bullous dermatoses.

Entities:  

Mesh:

Year:  1999        PMID: 10410853     DOI: 10.1016/s0733-8635(05)70102-9

Source DB:  PubMed          Journal:  Dermatol Clin        ISSN: 0733-8635            Impact factor:   3.478


  5 in total

1.  Overexpression of laminin-8 in human dermal microvascular endothelial cells promotes angiogenesis-related functions.

Authors:  Jie Li; Lisa Zhou; Hoang T Tran; Yi Chen; Ngon E Nguyen; Marvin A Karasek; M Peter Marinkovich
Journal:  J Invest Dermatol       Date:  2006-02       Impact factor: 8.551

2.  In vivo restoration of laminin 5 beta 3 expression and function in junctional epidermolysis bullosa.

Authors:  P B Robbins; Q Lin; J B Goodnough; H Tian; X Chen; P A Khavari
Journal:  Proc Natl Acad Sci U S A       Date:  2001-04-10       Impact factor: 11.205

3.  Diagnostic pitfalls in newborns and babies with blisters and erosions.

Authors:  Elke Nischler; Alfred Klausegger; Clemens Hüttner; Gabriele Pohla-Gubo; Anja Diem; Johann W Bauer; Helmut Hintner
Journal:  Dermatol Res Pract       Date:  2010-01-20

4.  Suprathel(®) -assisted surgical treatment of the hand in a dystrophic epidermolysis bullosa patient.

Authors:  Elif Sari; Tolga Eryilmaz; Gulsum Tetik; Hulda R Ozakpinar; Esabil Eker
Journal:  Int Wound J       Date:  2014-02-11       Impact factor: 3.315

Review 5.  Esophageal manifestations of dermatologic disease.

Authors:  James L Wise; Joseph A Murray
Journal:  Curr Gastroenterol Rep       Date:  2002-06
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.